keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical therapy

keyword
https://www.readbyqxmd.com/read/29344095/metachronous-metastasis-of-renal-cell-carcinoma-to-the-urinary-bladder-a-case-report
#1
Ruben De Groote, Alessandro Larcher, Marijn Goossens, De Raeve Hendrik, Van Der Steen Kris, Vincent De Coninck, Geert De Naeyer, Peter Schatteman, Frederiek D'Hondt, Alexandre Mottrie
We report a case of intravesical metastasis of a clear cell renal cell carcinoma. In renal cell carcinoma 16% of patients present with metastatic disease. Renal cell carcinoma can metastasize to nearly every organ, although metastatic spread to the urinary bladder is rare, with fewer than 70 described cases. The route and pattern of metastatic spread is not yet fully understood and different pathways are suggested. Gross haematuria is the presenting symptom in the majority of cases. These intravesical metastases may be synchronous or metachronous and can be solitary or part of polymetastatic disease...
January 2018: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29341502/advances-in-intravesical-therapy-for-bladder-pain-syndrome-bps-interstitial-cystitis-ic
#2
REVIEW
En Meng, Yu-Chao Hsu, Yao-Chi Chuang
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic symptom complex that may cause bothersome storage symptoms and pain or discomfort of the bladder, adversely affecting a patient's quality of life. The etiology of IC/BPS remains unclear, and its cause may be multifactorial. Diagnosis of IC/BPS is based on clinical features, and the possibility of other conditions must be ruled out first. Although no definitive treatment is currently available for IC/BPS, various intravesical therapies are used for IC/BPS, including heparin, hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dimethylsulfoxide, liposomes, and botulinum onabotulinumtoxinA (BoNT-A)...
January 2018: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/29330444/lidocaine-enhances-the-effects-of-chemotherapeutic-drugs-against-bladder-cancer
#3
Xihua Yang, Lili Zhao, Meiping Li, Lei Yan, Shengwan Zhang, Zhenguo Mi, Liansheng Ren, Jun Xu
This study aimed to investigate whether lidocaine, alone or in combination with other chemotherapeutic agents, inhibits the growth of human bladder cancer cells in vitro and orthotopically transplanted bladder tumors in vivo. The effects of lidocaine (1.25, 2.5 or 5 mg/mL), mitomycin C (MMC, 0.66 mg/mL), pirarubicin (0.75 mg/mL) and Su Fu'ning lotion (SFN, 0.0625 mg/mL) on the proliferation of human bladder cancer (BIU-87) cells were studied using the MTT assay. A Balb/c nude mouse model of bladder cancer was developed by orthotopic transplantation of BIU-87 cells, and the effects of intravesical instillation of lidocaine and MMC on bladder wet weight (a measure of tumor size) and survival (over 60 days) were studied...
January 12, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29322799/predictors-and-prognostic-implications-of-clinical-decisions-in-patients-with-primary-high-risk-non-muscle-invasive-bladder-cancer-results-of-a-cross-country-retrospective-study
#4
S Poletajew, R Biernacki, P Buraczynski, J Chojnacki, S Czarniecki, D Gajewska, T Pohaba, J Sondka-Migdalska, M Skrzypczyk, T Suchojad, D Wojtkowiak, B Zaforemski, L Zapala, A Zemla, P Radziszewski
Adjuvant diagnostic and therapeutic procedures are available to reduce the risk of recurrence or progression in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). However, their indications and efficacy remain a matter of debate. The aim of this study was to analyze therapeutic decisions in patients with primary high-risk NMIBC and to analyze the adherence to clinical guidelines in this field.545 consecutive patients, aged a median of 70.3 years, diagnosed with primary high-risk NMIBC in thirteen urological institutions, were enrolled into this retrospective study...
2018: Neoplasma
https://www.readbyqxmd.com/read/29320672/position-statement-a-clinical-approach-to-the-management-of-adult-non-neurogenic-overactive-bladder
#5
Eric Chung, Dominic Lee, Johan Gani, Michael Gillman, Christopher Maher, Janelle Brennan, Lydia Johns Putra, Laura Ahmad, Lewis Lw Chan
Overactive bladder (OAB) is a highly prevalent medical condition that has an adverse impact on various health-related quality-of-life domains, including a significant psychosocial and financial burden. This position statement, formulated by members of the Urological Society of Australia and New Zealand and the UroGynaecological Society of Australasia, summarises the current recommendations for clinical diagnosis and treatment strategies in patients with non-neurogenic OAB, and guides clinicians in the decision-making process for managing the condition using evidence-based medicine...
January 15, 2018: Medical Journal of Australia
https://www.readbyqxmd.com/read/29298474/current-pharmacologic-approaches-in-painful-bladder-research-an-update
#6
REVIEW
Karl-Erik Andersson, Lori Birder
The symptoms of interstitial cystitis (IC)/bladder pain syndrome (BPS) may have multiple causes and involve many contributing factors. Traditional treatments (intravesical instillations) have had a primary focus on the bladder as origin of symptoms without adequately considering the potential influence of other local (pelvic) or systemic factors. Systemic pharmacological treatments have had modest success. A contributing factor to the low efficacy is the lack of phenotyping the patients. Individualized treatment based on is desirable, but further phenotype categorization is needed...
December 2017: International Neurourology Journal
https://www.readbyqxmd.com/read/29290317/histiocytic-sarcoma-with-bladder-involvement-case-report-and-literature-review
#7
Mª Jesús Fernández-Aceñero, Pablo Pérez Alonso, Cristina Díaz Del Arco
We report an unusual case of histiocytic sarcoma with bladder involvement. An 80 year-old man with a previous history of diffuse large B-cell malignant lymphoma presented with hematuria and back pain. Serial urine cytologies revealed no urothelial malignant cells, but cystoscopy showed a large intravesical mass. The patient underwent transurethral resection (TUR) of the tumor. The bladder TUR specimen showed a widely infiltrating epithelioid neoplasm, with intense immunohistochemical positivity for CD45 and histiocytic markers (CD68, lysozime and fascin)...
January 2018: Revista Española de Patología
https://www.readbyqxmd.com/read/29288392/a-counterforce-to-diversion-of-cerebrospinal-fluid-during-ventriculoperitoneal-shunting-the-intraperitoneal-pressure-an-observational-study
#8
Brit Böse, Veit Rohde, Ingo Fiss, Florian Baptist Freimann
BACKGROUND: Intraperitoneal pressure (IPP) counteracts the diversion of cerebrospinal fluid (CSF) from the cranial to the peritoneal compartment during ventriculoperitoneal shunting. Animal studies suggest that the intrinsic IPP exceeds the intraperitoneal hydrostatic pressure. The intrinsic IPP in mobile patients is relevant for shunt therapy, but data about it is not available. METHODS: The IPP was measured indirectly in 25 mobile subjects (13 female) by applying a standard intravesical pressure measurement technique...
December 29, 2017: Acta Neurochirurgica
https://www.readbyqxmd.com/read/29287519/isolated-red-patches-seen-during-endoscopic-surveillance-of-bladder-cancer-when-should-we-biopsy
#9
Nkwam Nkwam, Shaun Trecarten, Stefan Momcilovic, Alvaro E Bazo, Gurminder S Mann, Benedict Sherwood, Richard Parkinson
OBJECTIVE: To establish whether the regular biopsy of red patches seen during endoscopic surveillance for bladder cancer is worthwhile and determine a suitable time frame for repeat biopsy of prior histologically benign persistent red patches in patients on endoscopic surveillance for bladder cancer. PATIENTS AND METHODS: 4,805 flexible cystoscopy reports over a 12-month period were retrospectively reviewed at a UK tertiary teaching hospital and those undergoing cystoscopic surveillance for bladder cancer and found to have solitary red patches at flexible cystoscopy were included in the study...
December 29, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/29250970/-image-guided-radiotherapy-for-muscle-invasive-bladder-cancer-with-intravesical-lipiodol-injection-a-new-option-for-bladder-sparing-treatment
#10
Jorgo Kliton, Csaba Polgár, Péter Tenke, Gábor Kovács, Tibor Major, Gábor Stelczer, Péter Ágoston
INTRODUCTION AND AIM: To implement lipiodol as a fiducial marker of the tumor bed for image-guided radiotherapy with simultaneous integrated boost technique as part of radiochemotherapy for muscle invasive bladder tumors. METHOD: Since April 2016, radiochemotherapy was performed in 3 male patients with muscle invasive, transitional cell bladder carcinoma. Prior to radiochemotherapy, tumor bed resection was performed for each patient, at the same time 10 ml of lipiodol solution was injected submucosally into the resection site, thus marking the tumor bed for escalated dose irradiation...
December 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29241263/systematic-review-of-oral-therapy-for-the-treatment-of-symptoms-of-bladder-pain-syndrome-the-brazilian-guidelines
#11
Thaís Guimarães Dos Santos, Isabela Albuquerque Severo de Miranda, Christiana Campani Nygaard, Lucas Schreiner, Rodrigo de Aquino Castro, Jorge Milhen Haddad
Interstitial cystitis (IC), including bladder pain syndrome (BPS), is a chronic and debilitating disease that mainly affects women. It is characterized by pelvic pain associated with urinary urgency, frequency, nocturia and negative urine culture, with normal cytology. In 2009, the Society for Urodynamics and Female Urology (SUFU) defined the term IC/BPS as "an unpleasant sensation (pain, pressure, and discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms for more than 6 weeks duration, in the absence of infection or other identifiable causes...
December 14, 2017: Revista Brasileira de Ginecologia e Obstetrícia
https://www.readbyqxmd.com/read/29221191/recommended-oral-sodium-bicarbonate-administration-for-urine-alkalinization-did-not-affect-the-concentration-of-mitomycin-c-in-non-muscle-invasive-bladder-cancer-patients
#12
Ho Kyung Seo, Sung Han Kim, Kyung-Ohk Ahn, Sang-Jin Lee, Weon Seo Park, Sohee Kim, Sang-Hyun Hwang, Do Hoon Lee, Jae Young Joung, Jinsoo Chung, Jungnam Joo, Kyung-Chae Jeong
Objective: Sodium bicarbonate has been reported to maximize the efficacy of intravesical instillation of mitomycin-C (IVI-MMC) therapy by urine alkalinization in non-muscle-invasive bladder cancer (NMIBC). This study aimed to analyze the changes in MMC concentration according to urinary pH and evaluate the efficacy of sodium bicarbonate to maintain the concentration of active form of MMC during IVI-MMC. Methods: We prospectively enrolled 26 patients with NMIBC after transurethral resection of bladder tumor...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29212486/emerging-concepts-and-spectrum-of-renal-injury-following-intravesical-bcg-for-non-muscle-invasive-bladder-cancer
#13
Azharuddin Mohammed, Zubair Arastu
BACKGROUND: Intravesical Bacilli Calmette-Guerin (IVBCG) therapy for non-muscle invasive bladder cancer (NMIBC) has long been in use successfully. Albeit rarely, we still face with its safety concerns more than 25 years on since its approval by US Food and Drug Agency in 1990. Local and systemic infection following intravesical BCG is widely reported as compared to immune mediated local or systemic hypersensitivity reactions involving kidneys; acute kidney injury (AKI) and other renal manifestations are well reported but not of chronic kidney disease (CKD)...
December 6, 2017: BMC Urology
https://www.readbyqxmd.com/read/29201501/alternative-therapies-in-patients-with-non-muscle-invasive-bladder-cancer
#14
REVIEW
Öner Şanlı, Yair Lotan
Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required...
December 2017: Turkish Journal of Urology
https://www.readbyqxmd.com/read/29190688/spatial-and-temporal-profile-of-cisplatin-delivery-by-ultrasound-assisted-intravesical-chemotherapy-in-a-bladder-cancer-model
#15
Noboru Sasaki, Kazuhiro Ishi, Nobuki Kudo, Shouta M M Nakayama, Kensuke Nakamura, Keitaro Morishita, Hiroshi Ohta, Mayumi Ishizuka, Mitsuyoshi Takiguchi
Non-muscle invasive bladder cancer is one of the most common tumors of the urinary tract. Despite the current multimodal therapy, recurrence and progression of disease have been challenging problems. We hereby introduced a new approach, ultrasound-assisted intravesical chemotherapy, intravesical instillation of chemotherapeutic agents and microbubbles followed by ultrasound exposure. We investigated the feasibility of the treatment for non-muscle invasive bladder cancer. In order to evaluate intracellular delivery and cytotoxic effect as a function to the thickness, we performed all experiments using a bladder cancer mimicking 3D culture model...
2017: PloS One
https://www.readbyqxmd.com/read/29164059/intravesical-gemcitabine-versus-intravesical-bacillus-calmette-gu%C3%A3-rin-for-the-treatment-of-non-muscle-invasive-bladder-cancer-an-evaluation-of-efficacy-and-toxicity
#16
Thiru Prasanna, Paul Craft, Gayathri Balasingam, Hodo Haxhimolla, Ganes Pranavan
Background: Intravesical Bacillus Calmette-Guérin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer (NMIBC) following transurethral resection; however, BCG failure and related toxicities are common. Objectives: To compare the efficacy and toxicity of intravesical BCG and gemcitabine in the treatment of NMIBC. Methods: Retrospective data were collected in the region of Canberra, Australia from January 2010 to December 2015...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29160225/phosphatidylserine-targeted-single-walled-carbon-nanotubes-for-photothermal-ablation-of-bladder-cancer
#17
Needa A Virani, Carole Davis, Patrick McKernan, Paul Hauser, Robert E Hurst, Joel Slaton, Ricardo P Silvy, Daniel E Resasco, Roger G Harrison
Bladder cancer has a 60-70% recurrence rate most likely due to residual tumour left behind after a transurethral resection (TUR). Failure to completely resect the cancer can lead to recurrence and progression into higher grade tumours with metastatic potential. We present here a novel therapy to treat superficial tumours with the potential to decrease recurrence. The therapy is a heat-based approach in which bladder tumour specific single-walled carbon nanotubes (SWCNTs) are delivered intravesically at a very low dose (0...
November 21, 2017: Nanotechnology
https://www.readbyqxmd.com/read/29152556/bladder-sparing-therapy-for-bcg-failures-i-intravesical-immunotherapy
#18
Edward M Messing
No abstract text is available yet for this article.
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29152553/oncological-outcomes-of-sequential-intravesical-gemcitabine-and-docetaxel-in-patients-with-non-muscle-invasive-bladder-cancer
#19
Niv Milbar, Max Kates, Meera R Chappidi, Filippo Pederzoli, Takahiro Yoshida, Alexander Sankin, Phillip M Pierorazio, Mark P Schoenberg, Trinity J Bivalacqua
Background: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH). Objective: To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies...
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29145329/new-onset-of-myasthenia-gravis-after-intravesical-bacillus-calmette-guerin-a-case-report-and-literature-review
#20
Tsubasa Takizawa, Marenori Kojima, Shigeaki Suzuki, Takashi Osada, Satoshi Kitagawa, Jin Nakahara, Shinichi Takahashi, Norihiro Suzuki
RATIONALE: Recently, drug-related myasthenia gravis (MG) has received attention, because the number of reported cases involving MG associated with immune checkpoint inhibitors, a new immunotherapy, is increasing. We present a case involving the new onset of MG, in which the symptoms started shortly after intravesical Bacillus Calmette-Guerin (BCG) for bladder cancer. PATIENT CONCERNS: A 69-year-old male with bladder cancer developed ptosis and diplopia 4 days after the completion of a treatment regimen with intravesical BCG weekly for 6 weeks...
November 2017: Medicine (Baltimore)
keyword
keyword
21306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"